Paul Thompson joined Mission Therapeutics in June 2016.

Paul has more than 15 years of experience in translational research and early clinical development. Before joining Mission as Medical Director for CNS, Paul worked as a Clinical Science Director at ONO Pharma UK, leading clinical development of multiple early phase assets across a variety of indications including inflammatory pain, portal hypertension, whilst driving translational strategies for preclinical programs. Prior to this, Paul spent 12 years at GlaxoSmithKline, transitioning from laboratory biomarker research, through experimental medicine study leadership, to leading global project teams as Director of Discovery Medicine in the Neurology TA.

Paul is a member of the British Pharmacological Society, Society for Neuroscience and American Academy of Neurology, and currently is PI for a Target Validation award from the Michael J Fox Foundation.

Paul holds an MBiochem from the University of Oxford and a PhD from UCL.